Home・Список акций・AbbVie Inc

AbbVie Inc

Открыт

СекторЗдравоохранение

249.89 0.87

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

243.85

Макс.

247.95

Ключевые показатели
By Trading Economics
Доход	2.9B 3.6B
Продажи	2B 17B
P/E Средняя по отрасли	69.237 68.51
Прибыль на акцию	3.65
Дивидендная доходность	1.34
Рентабельность продаж	21.283
Сотрудники	57,000
EBITDA	3B 6.7B

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+12.68% upside

Дивиденды
By Acuity
Дивидендная доходность Средняя по отрасли	1.34% 2.29%
Следующий отчет о доходах	30 окт. 2026 г.
Дата следующей выплаты дивидендов	14 авг. 2026 г.
Следующая эксдивидендная дата	14 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-21B 433B
Предыдущая цена открытия	249.02
Предыдущая цена закрытия	249.89

Новостные настроения

By Acuity

31%

69%

60 / 340 Рейтинг в Healthcare

AbbVie Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 авг. 2026 г., 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7 авг. 2026 г., 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 авг. 2026 г., 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 авг. 2026 г., 19:26 UTC

News

Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 авг. 2026 г., 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 авг. 2026 г., 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 июл. 2026 г., 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 июл. 2026 г., 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 июл. 2026 г., 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 июл. 2026 г., 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 июл. 2026 г., 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24 июл. 2026 г., 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23 июл. 2026 г., 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22 июл. 2026 г., 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21 июл. 2026 г., 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20 июл. 2026 г., 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Сравнение c конкурентами

Изменение цены

AbbVie Inc Прогноз

Целевая цена

By TipRanks

12.68% рост

Прогноз на 12 месяцев

Средняя 277.24 USD 12.68%

Максимум 300 USD

Минимум 225 USD

Основано на мнении 23 аналитиков Wall Street, спрогнозировавших целевые цены для AbbVie Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

23 ratings

Покупка

Удержание

Продажа

Основано на мнении 23 аналитиков, присваивавших рейтинги акциям AbbVie Inc – Данные за последние 3 месяца.

Настроения

By Acuity

60 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.